| Oct 29 |
CVRx Reports Third Quarter 2024 Financial and Operating Results
|
| Oct 21 |
CVRx (CVRX) Soars 17.2%: Is Further Upside Left in the Stock?
|
| Oct 21 |
CVRx announces new CPT Category I codes for Barostim heart failure therapy
|
| Oct 19 |
CVRx announces new CPT Category I codes for Barostim
|
| Oct 18 |
CVRx announces new CPT® Category I codes for Barostim
|
| Oct 15 |
CVRx to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call on October 29, 2024
|
| Sep 16 |
CVRX Stock Gains on Unveiling of Barostim's Positive Study Data
|
| Sep 12 |
CVRx touts positive two-year data for heart failure neuromodulation device
|
| Sep 12 |
CVRx announces new publication reinforcing the long-term quality of life benefits of Barostim
|
| Sep 3 |
CVRx Announces Appointment of Two New Board Members
|
